Biophytis Announces The Design Of Its Phase 2 OBA Clinical Study In Obesity With BIO101 (20-hydroxyecdysone)
Biophytis Announces The Design Of Its Phase 2 OBA Clinical Study In Obesity With BIO101 (20-hydroxyecdysone)
Biophytis 宣佈利用 BIO101（20-羥基ecdysone）設計其針對肥胖症的 2 期 OBA 臨床研究
BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight with secondary comorbidities, who are starting treatment with GLP-1 RAs for weight loss.
將在接受 GLP-1 RA 和低熱量節食治療的肥胖患者中評估 BIO101（20-羥基腐皮酮）。OBA 第 2 期研究將測試 BIO101（20-羥基ecdysone）對肥胖和超重患有繼發合併症的患者的療效和安全性，這些患者已開始使用 GLP-1 RA進行減肥治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。